Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Image-guided Histotripsy System for Complete, Uniform, and Non-Invasive Ablation of Heterogeneous Osteosarcoma Tumors

Award Number: R01CA289288
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

Image-guided Histotripsy System for Complete, Uniform, and Non-Invasive Ablation of Heterogeneous Osteosarcoma Tumors - Summary The goal of this project is to develop a novel histotripsy device for non-invasive treatment of heterogeneous osteosarcoma tumors (OS). OS are malignant bone tumors that develop in both children and adults. Long-term survival rates for patients with metastatic and non-metastatic OS are around 20% and 70%, respectively, highlighting the devastating nature of this disease. Limb salvage surgery or amputation are first-line treatments for primary appendicular OS, but these remain associated with high complication rates and decreased mobility and function. Novel treatments for OS are needed to improve outcomes. Histotripsy is a non-invasive ultrasound therapy that mechanically ablates tumors into acellular debris via controlled acoustic cavitation. Histotripsy can be tissue-selective, where neurovascular bundles, vessels, and bone can be preserved while the tumor is completely disrupted to acellular debris. Histotripsy appears to be well-suited for OS with the ability to serve as a non-surgical limb salvage treatment option, with promising results noted in preliminary studies. Despite this promise, OS treatment with histotripsy presents unique challenges: 1) OS tumors exhibit high inter- and intra- tumoral heterogeneity, with varying proportions of lytic and proliferative bone and soft tissue tumor proliferation, requiring optimized treatment strategies for complete and uniform ablation of all OS phenotypes. 2) OS tumors grow close to critical structures. While histotripsy has been shown to be tissue-selective for other applications, there remains a need to develop methods for selectively ablating OS tumors while preserving healthy bone, nerves, vessels, and connective tissue. 3) Histotripsy is typically guided by real-time ultrasound imaging, which is not feasible for a subset of OS tumors due to bone obstruction, requiring improved targeting and monitoring techniques. In this proposal, we will develop an integrated image-guided histotripsy system for the precise targeting and ablation of OS tumors. The system will consist of a phased array transducer with transmit-receive capability for 3D cavitation monitoring, image-fusion targeting (CT/MRI), and a fully automated robotic treatment technique with strategies for achieving uniform and complete ablation of heterogeneous OS tumors. We propose the following three aims. Aim 1: Design and construct an integrated histotripsy OS system consisting of an array transducer with transmit-receive capabilities for 3D cavitation imaging and image-fusion targeting. Aim 2: Develop patient specific treatment methods with optimized parameters for complete, uniform, and tissue- selective OS ablation. Aim 3: Test the in vivo safety and efficacy of the integrated OS system (Aim 1) and optimized parameters for uniform and safe treatment of OS (Aim 2) in canine OS patients at the Virginia Tech Animal Cancer Care and Research Center. This project will result in a human prototype histotripsy system with unique treatment and monitoring capabilities as well as parameters optimized for OS. The canine patients are the best large animal model to test the safety and efficacy of histotripsy and accelerate clinical translation, and the veterinary treatment is another application for histotripsy OS therapy before the FDA approval of human use.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $630,563 )
2026	2026	VIRGINIA POLYTECHNIC INSTITUTE & STATE UNIVERSITY	300 TURNER ST NW	BLACKSBURG	VA	24060	MONTGOMERY	USA	Cancer Detection and Diagnosis Research	000	3	4/9/2026	NON-COMPETING CONTINUATION	$630,563
														Subtotal = $630,563

Issue Date FY: 2025 ( Subtotal = $632,450 )
2025	2025	VIRGINIA POLYTECHNIC INSTITUTE & STATE UNIVERSITY	300 TURNER ST NW	BLACKSBURG	VA	24060	MONTGOMERY	USA	Cancer Detection and Diagnosis Research	001	2	5/22/2025	NON-COMPETING CONTINUATION	$63,244
2025	2025	VIRGINIA POLYTECHNIC INSTITUTE & STATE UNIVERSITY	300 TURNER ST NW	BLACKSBURG	VA	24060	MONTGOMERY	USA	Cancer Detection and Diagnosis Research	000	2	4/15/2025	NON-COMPETING CONTINUATION	$569,206
														Subtotal = $632,450

Issue Date FY: 2024 ( Subtotal = $628,220 )
2024	2024	VIRGINIA POLYTECHNIC INSTITUTE & STATE UNIVERSITY	300 TURNER ST NW	BLACKSBURG	VA	24060	MONTGOMERY	USA	Cancer Detection and Diagnosis Research	000	1	5/1/2024	NEW	$628,220
														Subtotal = $628,220

Grand Total All Awards = $1,891,233

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Image-guided Histotripsy System for Complete, Uniform, and Non-Invasive Ablation of Heterogeneous Osteosarcoma Tumors

Award Number: R01CA289288

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer